Overview

A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (ANV419-102).

Status:
Not yet recruiting

Trial end date:
2024-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and tolerability of ANV419 monotherapy followed by ANV419 in combination with lenalidomide plus low-dose dexamethasone or ANV419 in combination with daratumumab.

Phase:

Phase 1

Details

Lead Sponsor:

Anaveon AG

Treatments:

Daratumumab
Dexamethasone
Lenalidomide